
Giant, Glowing Gas Cloud Discovered Just 300 Light-Years Away
The surprise discovery of a huge cloud of molecular gas — the stuff that forms stars — just 300 light-years away is opening up new ways to study the conditions that enable star birth.
Stars form from collapsing clouds of molecular gas. We see this in the likes of the Orion Nebula, which gets energized by hot ultraviolet radiation of the young stars born within. However, finding molecular clouds before they begin producing stars is more difficult.
Such clouds are predominantly made from molecular hydrogen gas, which, when it isn't being energized by starlight, is very faint — almost invisible. (Atomic hydrogen, on the other hand, is easily detectable by radio telescopes). Astronomers usually use radio telescopes to detect carbon monoxide, which is available in much lower quantities in molecular clouds, as a proxy.
On supporting science journalism
If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.
But what about the clouds without much carbon monoxide?
Astronomers led by Blakesley Burkhart of Rutgers University–New Brunswick in New Jersey and Thavisha Dharmawardena of New York University, have pioneered an entirely new way of seeing the invisible. Using far-ultraviolet data from the Korean STSAT-1 satellite, they directly detected molecules of hydrogen fluorescing.
"This is the first-ever molecular cloud discovered by looking for far-ultraviolet emission of molecular hydrogen directly," Burkhart said in a statement. "This cloud is literally glowing in the dark."
The cloud is roughly crescent-shaped and sits on the edge of the Local Bubble, which is a volume of space where the interstellar medium is more rarefied than its surroundings, perhaps having been emptied by the shockwaves of hundreds of ancient supernovas. The sun and our solar system are passing through the Local Bubble, and have been doing so for the past five million years or so.
The cloud, named Eos after the goddess of Greek mythology who signified the dawn, contains approximately 3,400 solar masses worth of gas. It's also depleted in carbon monoxide, which is why it had gone undetected by conventional means.
Eos is predicted to disperse, or photodissociate, as a result of background photons impacting the cloud's molecules, in about 5.7 million years' time. This is too soon for it to begin forming stars, unless there is some other trigger that advances things, such as the gravitational disturbance of another passing cloud. Intriguingly, the average star-formation rate in our sun's neighborhood has been calculated at 200 solar masses per million years. Eos is losing mass to the wider interstellar medium at a rate of 600 solar masses per million years, three times the rate at which molecular gas is converted into stars. Therefore, this dispersion of molecular clouds as a result of photodissociation from light emitted by nearby stars seems to act as a feedback mechanism to regulate the rate of star formation, Burkhart's team believes. This is useful information for telling us more about the conditions needed to enable star formation in other, more distant clouds.
"When we look through our telescopes, we catch whole solar systems in the act of forming, but we don't know in detail how that happens," said Burkhart. "Our discovery of Eos is exciting because we can now directly measure how molecular clouds are forming and dissociating, and how a galaxy begins to transform interstellar gas and dust into stars and planets."
And the discovery of other, similar clouds could be just on the horizon.
"The use of the far-ultraviolet fluorescence emission technique could rewrite our understanding of the interstellar medium, uncovering hidden clouds across the galaxy and even out to the furthest detectable limits of cosmic dawn," said Dharmawardena.
Eos may not see the dawn of new stars, but its existence is testament to a greater dawn, going all the way back to near the beginning of the universe, in which stars have brought daylight to a dark cosmos.
The findings were published on April 28 in the journal Nature Astronomy.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Cepheid Receives Health Canada Licence for Xpert® HIV-1 Viral Load XC
Next-Generation Molecular Test for Monitoring Viral Load and HIV-1 Infection SUNNYVALE, Calif., June 4, 2025 /CNW/ -- Cepheid today announced that Health Canada has issued Cepheid a medical device licence for Xpert® HIV-1 Viral Load XC, a next-generation extended-coverage (XC) test intended to aid in assessing HIV viral load levels, which are used to monitor effectiveness of antiretroviral treatment. Xpert® HIV-1 Viral Load XC dual target test provides extended strain coverage ensuring a high level of performance with a simple workflow to improve patient access to the standard of care and help achieve UNAIDS HIV targets by 2030.1 "Xpert® HIV-1 Viral Load XC leverages dual target technology to improve detection while maintaining the flexibility to be performed on-demand in as little as 90 minutes." said Vitor Rocha, President of Cepheid. "Access to the test can enhance patient care, as measurement of HIV viral load informs treatment plans while fast results enable earlier interventions with counseling and therapy." The test is designed for use on any of Cepheid's GeneXpert® Systems which provide simple, reference lab quality PCR testing on location in laboratory environments at medical centers and hospitals or in community health clinics and physician offices. Xpert® HIV-1 Viral Load XC will begin shipping to customers in Canada in June 2025. Visit for more information. Malisa et al 2023 Nature Scientifc Reports | (2023) 13:4578https:// About CepheidBased in Sunnyvale, Calif., Cepheid is a leading molecular diagnostics company that is an operating company within Danaher Corporation's Diagnostics platform. Cepheid is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit IVD. In Vitro Diagnostic Medical Device. May not be available in all countries For Cepheid Media Inquiries:Darwa SOURCE Cepheid View original content to download multimedia: Erreur lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données


Gizmodo
4 hours ago
- Gizmodo
A New Look at ‘Fantastic Four: First Steps' Is All About Family
As ticket sales begin today, Marvel has dropped another new look at Fantastic Four: First Steps in action–and although there's plenty glimpses of the First Family in action as they brace for the coming of Galactus, this new footage does properly welcome up to the next member of the team. While Reed and Sue's incoming addition to the Richards' has been teased in prior trailers, this new footage gives us our first actual look at little baby Franklin–who comic book fans know will grow up into one of the most powerful young heroes in the Marvel multiverse. Once a mutant (ah, comic books), Franklin Richards develops psionic powers at a young age, and is eventually one of the most potent reality manipulators along the already rare breed of those to use that powerset in Marvel's comics. Eventually, alongside his younger sister Valeria, Franklin becomes a member of the FF team in his own rights–but at least as far as First Steps goes, we're probably not going to see him tussling with the Silver Surfer and Galactus just yet, considering he's still in diapers. The rest of the footage teased is, of course, about that impending tussle with the devourer of worlds (although Marvel is keen on not quite showing us the scope of the MCU's take on Galactus just yet, content to leave him in glimpses and shadows), but we do get some fun glimpses, including a bit more of the Fantasticar in flight, and, intriguingly, the Marvel-1, the Fantastic Four's rocket ship, hurtling towards a planet facing horrendous damage to its surface. Whether that's another world that's fallen to Galactus' hunger already, or if it's even earth (or a glimpse of its potential fate should Galactus win) remains to be seen, but we do know that at some point in the climax of First Steps we're going to have to get some set up for Thunderbolts' post-credits scene, which saw Marvel-1 show up in orbit of Earth-616. Maybe we're setting up the Fantastic Four for a fight that not even they can win… or maybe they do, only for an incursion to sunder their reality anyway. We'll find out next month, when Fantastic Four: First Steps hits theaters on July 25.
Yahoo
5 hours ago
- Yahoo
NodThera Charts Obesity Future with First Patients Dosed in Phase 2 RESOLVE-1 Trial of Oral NLRP3 Inflammasome Inhibitor NT-0796
NodThera Charts Obesity Future with First Patients Dosed in Phase 2 RESOLVE-1 Trial of Oral NLRP3 Inflammasome Inhibitor NT-0796Philadelphia, PA, June 4, 2025 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, today announces that the first patients have been dosed in its Phase 2 RESOLVE-1 (RESolution Of infLammation to treat obesity and cardioVascular disEase) clinical trial investigating the potential of its lead candidate, oral NLRP3 inflammasome inhibitor NT-0796, in patients with obesity. NodThera's pioneering approach to obesity treatment is built on the growing understanding of the impact of chronic inflammation on the body and its fundamental role in the complex cycle of weight regulation which balances calorie intake, energy expenditure and satiety. While current drugs have made significant achievements in the management of obesity, their mechanisms primarily suppress the desire to eat (calorie restriction) or they promote a feeling of fullness, ultimately reducing food intake. NodThera's approach goes beyond the reduction of food intake by resetting the body's weight regulatory system and correcting the underlying imbalance, to return the body to its natural metabolic state. Daniel Swisher, Chief Executive Officer of NodThera, commented: 'With its novel molecular mechanism, the convenience of oral dosing without titration, and a well-tolerated safety profile, this fully brain-penetrant NLRP3 inflammasome inhibitor is projected to have a transformative impact on obesity by bringing the body back to balance. I am delighted that, following our recently closed $50 million Series D financing, we have accelerated our lead program into this robust Phase 2 trial, building on an impressive preclinical and clinical data set. This will support the progression of NT-0796 as an enhanced treatment for weight management, to enable patients to achieve sustained and healthy weight loss.' RESOLVE-1 is a randomized, double-blind, placebo-controlled Phase 2 trial that will evaluate the efficacy and safety of NT-0796 in patients with obesity, with or without type 2 diabetes, over 24 weeks. 160 patients are expected to be randomized into three treatment groups, receiving twice daily oral NT-0796, once daily oral NT-0796 or placebo. The trial's primary endpoint is the change in body weight in participants from baseline to week 24. Secondary endpoints include the impact of NT-0796 on body composition, metabolic biomarkers, and HbA1c levels in participants with type 2 diabetes. Headline data from the study are anticipated in Q2 2026. Returning the body to its natural metabolic balance – homeostasis Earlier preclinical and clinical work undertaken by the Company has demonstrated that NLRP3, an intracellular sensor and master switch that modulates inflammation, plays a key role in controlling obesity and obesity-associated inflammation. The fully brain-penetrant NT-0796 reduces inflammation in the brain, as well as throughout the body, to restore multiple dysregulated cardiometabolic pathways. The inhibition of NLRP3 results in the loss of fat mass, while preserving lean muscle mass, and restores the body's natural metabolic balance (homeostasis), enabling sustainable, enhanced and healthy weight loss. Positive clinical data announced by the Company in June 2024, from a Phase 1b/2a cardiovascular risk study in patients with obesity, confirmed NT-0796's profound anti-inflammatory effect and supported its anti-obesity potential. This followed the publication of preclinical data in the Journal of Pharmacology and Experimental Therapeutics, demonstrating the potential of NT-0796 to reverse diet-induced obesity and inflammation in an animal model of the disease, matching weight loss driven by the GLP-1 receptor agonist, semaglutide. Most recently, data published in the journal Obesity showed the enhanced weight loss effect of NT-0796 when combined with semaglutide in a preclinical obesity model. The potential of NT-0796 to improve the efficacy and tolerability of existing GLP-1RA obesity therapies will be further investigated in NodThera's upcoming Phase 2 combination trial, RESOLVE-2, expected to commence in H2 2025. Alan Watt, President and Chief Scientific Officer of NodThera, added: 'Through central NLRP3 inhibition and the correction of multiple dysregulated pathways in the brain and throughout the body, NT-0796 has the potential to deliver robust weight loss and broad cardiometabolic benefits that go beyond those seen with current therapies. NodThera's treatment approach, restoring the body's natural metabolic balance, would be game-changing.' For more information about NodThera please contact: NodTheraTel: +44 (0) 1223 608130Email: info@ ICR Healthcare Amber Fennell, David Daley Tel: +44 (0)20 3709 5700Email: nodthera@ About NodTheraNodThera is a leading clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases. Led by an experienced management team, NodThera is combining a deep understanding of NLRP3 inhibition, pharmaceutical neuroscience expertise and precision chemistry. Its two lead clinical candidates are oral, small molecule NLRP3 inflammasome inhibitors, which have demonstrated differentiated, potentially best-in-class clinical profiles with significant anti-inflammatory effects and high brain penetration, offering distinct opportunities to treat multiple indications. The Company is backed by top-tier investors including 5AM Ventures, Blue Owl Capital, Epidarex Capital, F-Prime Capital, Novo Holdings, Sanofi Ventures and Sofinnova Partners. NodThera is headquartered in Philadelphia, Pennsylvania, with additional operations in Cambridge, UK. Learn more at or follow the Company on in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data